Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
RNA Interference01:23

RNA Interference

26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
Types of RNA01:20

Types of RNA

5.7K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced splicing modulation by NMA-modified antisense oligonucleotides.

Nucleic acids research·2026
Same author

Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy.

Nature communications·2026
Same author

Synthesis, Incorporation, and Translation Properties of Threose Nucleic Acid Modified Trinucleotide Cap Analogs.

ACS omega·2025
Same author

Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation.

Nucleic acids research·2025
Same author

Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease.

Nucleic acids research·2025
Same author

A Workflow for Transcriptome-Wide Assessment of Antisense Oligonucleotide Selectivity.

Nucleic acid therapeutics·2025

Related Experiment Video

Updated: Jun 13, 2025

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
11:00

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

13.7K

Elevating microRNA levels by targeting biogenesis with steric-blocking antisense oligonucleotides.

Mallory A Havens1,2,3, Anthony J Hinrich4, Frank Rigo5

  • 1Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA havensmy@lewisu.edu hastingm@umich.edu.

RNA (New York, N.Y.)
|September 10, 2024
PubMed
Summary

Researchers developed a novel antisense oligonucleotide (ASO) strategy to increase microRNA (miRNA) levels by enhancing their biogenesis. This approach successfully restored reduced miR-1225 levels, offering a potential therapeutic avenue for diseases linked to miRNA dysregulation.

Keywords:
PKD1antisense oligonucleotidesautosomal dominant polycystic kidney diseasemiR-1225microRNA

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.6K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
11:00

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

13.7K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.6K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.6K

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) regulate gene expression and are implicated in diseases like cancer and autosomal dominant polycystic kidney disease (ADPKD).
  • Dysregulated miRNA levels present therapeutic targets, but strategies to increase miRNA abundance are less explored than those to decrease activity.
  • Antisense oligonucleotides (ASOs) are typically used to inhibit miRNA function, not to enhance miRNA biogenesis.

Purpose of the Study:

  • To demonstrate a novel antisense oligonucleotide (ASO)-based strategy for increasing miRNA abundance by enhancing biogenesis from the primary transcript.
  • To investigate the therapeutic potential of restoring miR-1225 levels, which are reduced in certain autosomal dominant polycystic kidney disease (ADPKD) cases due to sequence variants.
  • To validate the efficacy of a steric-blocking ASO in recovering reduced miR-1225 levels and observe its downstream effects on target gene expression.

Main Methods:

  • Utilized the PKD1/miR-1225 gene locus as a model system, where miR-1225 is intronic to PKD1.
  • Investigated specific PKD1 sequence variants associated with ADPKD that affect miR-1225 levels without altering PKD1 expression.
  • Applied a steric-blocking antisense oligonucleotide (ASO) targeting the primary transcript to enhance miR-1225 biogenesis and measured resultant changes in miRNA and target mRNA levels.

Main Results:

  • Identified a specific PKD1 sequence variant that reduces miR-1225 abundance without impacting PKD1 expression.
  • Demonstrated that treatment with a steric-blocking ASO successfully restored the reduced miR-1225 levels.
  • Observed that the ASO-induced increase in miR-1225 correlated with a decrease in the abundance of its predicted cellular mRNA targets.

Conclusions:

  • This study establishes a viable ASO-based strategy to elevate miRNA abundance by enhancing biogenesis from the primary transcript.
  • The steric-blocking ASO approach shows significant potential for therapeutic applications in diseases treatable by modulating miRNA biogenesis.
  • This method offers a promising alternative for diseases where increasing specific miRNA levels, rather than inhibiting them, is therapeutically beneficial.